1373443-26-5

Basic information

• Product Name: (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid methyl ester
• Synonyms: (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid methyl ester
• CAS NO: 1373443-26-5
• Molecular Weight: 312.409
• Mol File: 1373443-26-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid methyl ester(1373443-26-5)
• EPA Substance Registry System: (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid methyl ester(1373443-26-5)

Safety Data

• Hazardous Substances Data: 1373443-26-5(Hazardous Substances Data)

Upstream product

• 726-94-3 1-(4-methoxyphenyl)adamantane 
• 100-66-3 methoxybenzene 
• 768-90-1 1-Adamantyl bromide 
• 29799-07-3 4-adamantylphenol 
• 922-67-8 propynoic acid methyl ester 

Downstream Products

• 1373443-03-8 (E)-3-[3-(4-adamantan-1-yl-phenoxy)-acryloylamino]-benzoic acid methyl ester 
• 1373443-08-3 (E)-3-(4-adamantan-1-ylphenoxy)-N-(3-sulfamoylphenyl)acrylamide 
• 1373443-22-1 (E)-3-[3-(4-adamantan-1-yl-phenoxy)-acryloylamino]-N-(3-imidazole-1-yl-propyl)-benzamide 
• 1373443-14-1 (E)-3-(3-(4-adamantan-1-yl-phenoxy)acrylamido)benzoic acid 2-(dimethylamino)ethylester 
• 1373443-15-2 (E)-3-(3-(4-adamantan-1-ylphenoxy)acrylamido)benzoic acid 2-(pyrrolidin-1-yl)ethylester 
• 1373443-16-3 (E)-3-[3-(4-adamantan-1-ylphenoxy)acrylamido]benzoic acid morpholinoethyl ester 
• 1373443-17-4 (E)-3-[3-(4-adamantan-1-yl-phenoxy)-acryloylamino]-benzamide 
• 1373443-19-6 (E)-3-[3-(4-adamantan-1-yl-phenoxy)-acryloylamino]-N-furan-2-ylmethyl-benzamide 
• 1373443-30-1 (E)-3-(4-adamantan-1-yl-phenoxy)-acrylic acid 
• 1414335-38-8 methyl 3-(3-(4-(adamantan-1-yl)phenoxy)propanamido)benzoate 
• 926201-37-8 3-(4-adamantan-1-yl-phenoxy)-propanoic acid 

Relevant articles and documents

NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound exhibiting inhibitory activity of at least one of malate dehydrogenases I (MDH1) and malate dehydrogenases 2 (MDH2), and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The inventors of the present invention have experimentally confirmed that the compound exhibiting the MDH1 and/or MDH2 inhibitory activity has an inhibitory effect on mitochondrial respiration in cancer cells, an excellent inhibitory effect on cancer cell growth, etc. Thus, the compound of the present invention is expected to be effectively used as a pharmaceutical composition for treating cancer.

Phenoxyacrylic derivatives and use thereof

The present invention relates to a phenoxyacrylic derivative and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a nonalcoholic fatty liver disease. The compound according to the present invention has an

Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as Hypoxia-Inducible Factor (HIF) 1α inhibitors

A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) 1α inhibitors. The present structure-activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1α under hypoxic conditions (IC50 = 0.12 μM in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1α accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-1α inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.